ClinicalTrials.gg
CompletedNCT02863575Updated Apr 8, 2019Results posted

A Dental Pain Study Comparing The Analgesic Efficacy Of Ibuprofen/Caffeine

A Phase 3 interventional study of Ibuprofen/Caffeine and Ibuprofen in Pain, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 16 Years to 40 Years. Per ClinicalTrials.gov, last updated 2019-04-08.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
374
Allocation
Randomized
Ages
16 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies testing ibuprofen in Pain — 6 open to participants now, 6 under way, none of them phase 3. Ibuprofen · Pain.

Enrollment
8th of 86
374 · median 100
Started
2017
with 7 others
Phase 3
22 of 86
none open now
Registered
53rd of 86
by date
Lead sponsor
8 of 86
Pfizer

Among the 86 studies testing ibuprofen in Pain, this one is the 8th largest by enrollment, is one of 8 that started in 2017, is one of 22 in phase 3, and was the 53rd registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

6 of the 86 studies testing ibuprofen in Pain are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About ibuprofen

Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 16 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing ibuprofen in Pain, or all of them as a file.
02

Study summary

An efficacy study assessing analgesic effect of ibuprofen/caffeine in post-surgical dental pain.

Read the detailed description

The purpose of this study is to assess the analgesic efficacy of a fixed dose combination of ibuprofen/caffeine compared to ibuprofen alone and also to placebo.

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • third molar extraction
  • ibuprofen
  • ibuprofen/caffeine
  • post-surgical dental pain
04

Who can participate

Ages eligible
16 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females 16 years to 40 years of age (inclusive).
  • Subjects who have undergone outpatient surgical extraction of 3 or more third molars, of which at least 2 must be a partial or complete bony mandibular impaction within 30 days of Screening and have met baseline pain criteria as described in this protocol
  • Examined by the attending dentist or physician and medically cleared to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, metabolic or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing) determined by the Investigator to place the subject at increased risk including the presence or history within 2 years of screening of the following medical conditions/disorders:

    • Bleeding disorder;
    • Gastrointestinal ulcer or gastrointestinal bleeding;
    • Paralytic ileus or other gastrointestinal obstructive disorders.
  • Pregnant female subjects; breastfeeding female subjects; fertile male subjects and female subjects of who are unwilling or unable to use a highly effective method of
  • to ibuprofen, naproxen, aspirin, or any other NSAID, caffeine, or other component of the product.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
374 participants (actual)

Study arms

  • Experimental
    Ibuprofen/Caffeine

    Ibuprofen 400 mg/ Caffeine 100 mg fixed-dose combination

    Drug: Ibuprofen/Caffeine

  • Active comparator
    Ibuprofen

    Ibuprofen 400 mg

    Drug: Ibuprofen

  • Placebo comparator
    Placebo

    Placebo comparator

    Drug: Placebo

Interventions

  • DrugIbuprofen/Caffeine

    Drug pages: Ibuprofen · Caffeine

    Ibuprofen/Caffeine fixed-dose combination

  • Ibuprofen capsule

  • DrugPlacebo

    Placebo treatment

06

What researchers measure

Primary outcomes

  1. Time Weighted Sum of Pain Relief Rating (PRR) and Pain Intensity Difference (PID) Scores From 0 to 8 Hours Post-dose (SPRID 0-8): Ibuprofen + Caffeine Versus Ibuprofen

    SPRID 0-8: time-weighted sum of PRID scores from 0 to 8 hours. PRID: sum of PID and PRR at each post-dose time point. PRR score: at each post-dose time point participants answered to question "How much relief do you have from your starting pain?" on a 5-point scale: 0= none, 1= a little, 2= some, 3= a lot, 4= complete; higher scores = more relief from pain. Numerical pain severity rating (NPSR) scale: at baseline and each post-dose time point participants answered to question "How much pain do you have at this time?" on an 11-point scale: range from 0= no pain to 10= worst possible pain; higher scores = worse pain. PID score: NPSR score at baseline (0 hour) minus NPSR score at each post-dose time point; overall possible PID score range at a post-dose time point: -10 to 10, higher positive value = greater improvement. Overall possible SPRID 0-8 score range: -80 to 112, higher scores = more improvement in pain.

    Time frame: From 0 to 8 hours post-dose on Day 1

Secondary outcomes

  1. Time Weighted Sum of Pain Relief Rating and Pain Intensity Difference Scores From 0 to 2 (SPRID 0-2), 0 to 4 (SPRID 0-4), 0 to 6 (SPRID 0-6) and 0 to 8 Hours Post-dose (SPRID 0-8)

    SPRID 0-2, SPRID 0-4, SPRID 0-6, SPRID 0-8: time-weighted sum of PRID scores from 0 to 2, 0 to 4, 0 to 6 and 0 to 8 hours respectively. PRID at each post-dose time point = PID + PRR. PRR score: at each post-dose time point participants answered to question "How much relief do you have from your starting pain?" on 5-point scale: 0=none, 1=a little, 2=some, 3=a lot, 4=complete; higher scores=more relief from pain. NPSR scale: at baseline and each post-dose time point participants answered to question "How much pain do you have at this time?" on 11-point scale: range from 0=no pain to 10=worst possible pain; higher scores=worse pain. PID score: NPSR score at baseline (0 hour) minus NPSR score at each post-dose time point; overall possible PID score range at a post-dose time point: -10 to 10, higher positive value=greater improvement. Score range for: SPRID 0-2= -20 to 28; SPRID 0-4= -40 to 56; SPRID 0-6= -60 to 84; SPRID 0-8= -80 to 112. Higher SPRID scores=more improvement in pain.

    Time frame: From 0 to 2, 0 to 4, 0 to 6 and 0 to 8 hours post-dose on Day 1

  2. Time Weighted Sum of Pain Intensity Difference Scores From 0 to 2 Hours (SPID 0-2), 0 to 4 (SPID 0-4), 0 to 6 (SPID 0-6) and 0 to 8 Hours Post-dose (SPID 0-8)

    SPID 0-2, SPID 0-4, SPID 0-6, SPID 0-8: time-weighted sum of PID scores from 0 to 2, 0 to 4, 0 to 6 and 0 to 8 hours post-dose respectively. NPSR scale: at baseline and each post-dose time point participants answered to question "How much pain do you have at this time?" on an 11-point scale: score range from 0 = no pain to 10 = worst possible pain; higher scores = worse pain. PID score: NPSR score at baseline (0 hour) minus NPSR score at each post-dose time point; overall possible PID score range at a post-dose time point: -10 to 10, higher positive value = greater improvement. Overall possible range: SPID 0-2 = -20 to 20; SPID 0-4 = -40 to 40; SPID 0-6 = -60 to 60; SPID 0-8 = -80 to 80. Higher SPID scores = more improvement in pain.

    Time frame: From 0 to 2, 0 to 4, 0 to 6 and 0 to 8 hours post-dose on Day 1

  3. Time Weighted Sum of Pain Relief Rating Scores From 0 to 2 (TOTPAR 0-2), 0 to 4 (TOTPAR 0-4), 0 to 6 (TOTPAR 0-6) and 0 to 8 Hours Post-dose (TOTPAR 0-8)

    TOTPAR 0-2, TOTPAR 0-4, TOTPAR 0-6, TOTPAR 0-8: time-weighted sum of PRR scores from 0 to 2, 0 to 4, 0 to 6 and 0 to 8 hours post-dose respectively. PRR score: at each post-dose time point participants answered to the question "How much relief do you have from your starting pain?" on a 5-point scale: 0= none, 1= a little, 2= some, 3= a lot, 4= complete; higher scores = more relief from pain. Overall possible range: TOTPAR 0-2 = 0 to 8; TOTPAR 0-4 = 0 to 16; TOTPAR 0-6 = 0 to 24; TOTPAR 0-8 = 0 to 32. Higher TOTPAR scores = more improvement in pain.

    Time frame: From 0 to 2, 0 to 4, 0 to 6 and 0 to 8 hours post-dose on Day 1

  4. Sum of Pain Relief Rating and Pain Intensity Difference (PRID) Scores at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, and 8 Hours Post-dose

    PRID: sum of PID and PRR at each post-dose time point. PRR score: at each post-dose time point participants answered to a question "How much relief do you have from your starting pain?" on a 5-point scale: 0= none, 1= a little, 2= some, 3= a lot, 4= complete; higher scores = more relief from pain. NPSR scale: at baseline and each post-dose time point participants answered to a question "How much pain do you have at this time?" on an 11-point scale: range from 0= no pain to 10= worst possible pain; higher scores = worse pain. PID score: NPSR score at baseline (0 hour) minus NPSR score at each post-dose time point; overall possible PID score range at a post-dose time point: -10 to 10, higher positive value = greater improvement. At a single post-dose time point overall possible range for PRID score: -10 to 14, higher scores = more improvement in pain.

    Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, and 8 hours post-dose on Day 1

  5. Pain Relief Rating Scores at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, and 8 Hours Post-dose

    PRR score: at each post-dose time point participants answered to a question "How much relief do you have from your starting pain?" on a 5-point scale: 0= none, 1= a little, 2= some, 3= a lot, 4= complete; higher scores = more relief from pain.

    Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4 5, 6, 7, and 8 hours post-dose on Day 1

  6. Pain Intensity Difference Scores at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, and 8 Hours Post-dose

    NPSR scale: at baseline and each post-dose time point participants answered to a question "How much pain do you have at this time?" on an 11-point scale: range from 0= no pain to 10= worst possible pain; higher scores = worse pain. PID score: NPSR score at baseline (0 hour) minus NPSR score at each post-dose time point; overall possible PID score range at a single post-dose time point: -10 to 10, higher positive value = greater improvement in pain.

    Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4 5, 6, 7, and 8 hours post-dose on Day 1

  7. Time to Onset of Achieving Meaningful Relief

    When the participants were administered study medication at time 0 hours they were given the 2 stopwatches: 1 stopwatch was labelled as "first perceptible relief" and another as "meaningful relief." Participants were instructed to stop the stopwatch labelled as "meaningful relief" at the moment when they first experienced meaningful relief, that is, when the relief from the pain was meaningful to them. The stopwatch remained active for 8 hours (until stopped by the participants, or until rescue medication was administered).

    Time frame: Up to 8 hours post-dose on Day 1

  8. Time to Onset of First Perceptible Relief

    When the participants were administered study medication at time 0 hours they were given the 2 stopwatches: 1 stopwatch was labelled as "first perceptible relief" and another as "meaningful relief." Participants were instructed to stop the stopwatch labelled as "first perceptible relief" at the moment when they first began to feel any pain relieving effect. It was when they first felt a little/noticeable pain relief. It did not mean that they felt completely better (though they might), but when they first felt any difference in pain that they had at present. The stopwatch remained active for 8 hours (until stopped by the participants, or until rescue medication was administered).

    Time frame: Up to 8 hours post-dose on Day 1

  9. Time to Treatment Failure

    Treatment failure was defined as time to first dose of rescue medication or study discontinuation of the participants due to lack of efficacy.

    Time frame: Up to 8 hours post dose on Day 1

Other outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pre-treatment state. AEs are classified according to severity in 3 categories as mild (did not interfere with participant's usual function), moderate (interfered to some extent with participant's usual function) and severe (interfered significantly with participant's usual function).

    Time frame: Screening up to Day 17 after the last dose of study drug (approximately maximum of 48 days)

  2. Number of Participants With Treatment Emergent Treatment Related Adverse Events (AEs)

    Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pre-treatment state. Relatedness of an AE to study drug was assessed by investigator.

    Time frame: Screening up to Day 17 after the last dose of study drug (approximately maximum of 48 days)

  3. Number of Participants With Clinically Significant Vital Signs Abnormalities

    Vital signs included: heart rate, blood pressure, respiratory rate, and temperature. Normal range for the vital signs were: systolic blood pressure 90 to 140 millimeter of mercury (mmHg), diastolic blood pressure 60 to 90 mmHg, heart rate 50 to 110 beats per minute, respiratory rate 12 to 22 breaths per minute, and oral temperature 97.0 to 99.6 Fahrenheit (F). Value for vital signs outside the normal range was consider as abnormal. Clinical significance of vital signs abnormalities was determined at the investigator's discretion.

    Time frame: Screening up to Day 17 after the last dose of study drug (approximately maximum of 48 days)

  4. Number of Participants Who Used Concomitant Medications, and Rescue Medications

    Rescue medication: participants who did not experience adequate relief after the 1 hour (post study drug dose) evaluation were given tramadol hydrochloride 50 to 100 mg orally or codeine sulfate 15 to 60 mg orally, based on the discretion of the Investigator, as rescue medication. If needed, 2 additional doses of rescue medications based on the discretion of the Investigator at the study center was given. Total maximum dose of tramadol was 300 mg and of codeine sulfate was 180 mg. Concomitant medication: medication received by participant other than study medication and rescue medication.

    Time frame: Day 1

  5. Number of Participants Who Used Medications Prior to This Study

    In this outcome measure number of participants who were using any type of medications, prior to start of the study were reported.

    Time frame: At Screening

07

Results

Posted Apr 8, 2019

Participant flow

Participant flow — Overall Study
MilestoneIbuprofen 400 mg + Caffeine 100 mgIbuprofen 400 mgPlacebo
Started16116152
Completed16015951
Not completed121
Withdrew: Participants unable to swallow capsule100
Withdrew: Withdrawal by subject011
Withdrew: Adverse event010

Outcome measures

PrimaryTime Weighted Sum of Pain Relief Rating (PRR) and Pain Intensity Difference (PID) Scores From 0 to 8 Hours Post-dose (SPRID 0-8): Ibuprofen + Caffeine Versus Ibuprofen

SPRID 0-8: time-weighted sum of PRID scores from 0 to 8 hours. PRID: sum of PID and PRR at each post-dose time point. PRR score: at each post-dose time point participants answered to question "How much relief do you have from your starting pain?" on a 5-point scale: 0= none, 1= a little, 2= some, 3= a lot, 4= complete; higher scores = more relief from pain. Numerical pain severity rating (NPSR) scale: at baseline and each post-dose time point participants answered to question "How much pain do you have at this time?" on an 11-point scale: range from 0= no pain to 10= worst possible pain; higher scores = worse pain. PID score: NPSR score at baseline (0 hour) minus NPSR score at each post-dose time point; overall possible PID score range at a post-dose time point: -10 to 10, higher positive value = greater improvement. Overall possible SPRID 0-8 score range: -80 to 112, higher scores = more improvement in pain.

Time frame:
From 0 to 8 hours post-dose on Day 1
Reported as:
Least squares mean · units on a scale
Time Weighted Sum of Pain Relief Rating (PRR) and Pain Intensity Difference (PID) Scores From 0 to 8 Hours Post-dose (SPRID 0-8): Ibuprofen + Caffeine Versus Ibuprofen
units on a scaleIbuprofen 400 mg + Caffeine 100 mgIbuprofen 400 mg
Time Weighted Sum of Pain Relief Rating (PRR) and Pain Intensity Difference (PID) Scores From 0 to 8 Hours Post-dose (SPRID 0-8): Ibuprofen + Caffeine Versus Ibuprofen55.5 ± 1.852.8 ± 1.8
Statistical analysis
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.306 · Least square (ls) means difference: 2.68 · 95% CI -2.46 to 7.82
SecondaryTime Weighted Sum of Pain Relief Rating and Pain Intensity Difference Scores From 0 to 2 (SPRID 0-2), 0 to 4 (SPRID 0-4), 0 to 6 (SPRID 0-6) and 0 to 8 Hours Post-dose (SPRID 0-8)

SPRID 0-2, SPRID 0-4, SPRID 0-6, SPRID 0-8: time-weighted sum of PRID scores from 0 to 2, 0 to 4, 0 to 6 and 0 to 8 hours respectively. PRID at each post-dose time point = PID + PRR. PRR score: at each post-dose time point participants answered to question "How much relief do you have from your starting pain?" on 5-point scale: 0=none, 1=a little, 2=some, 3=a lot, 4=complete; higher scores=more relief from pain. NPSR scale: at baseline and each post-dose time point participants answered to question "How much pain do you have at this time?" on 11-point scale: range from 0=no pain to 10=worst possible pain; higher scores=worse pain. PID score: NPSR score at baseline (0 hour) minus NPSR score at each post-dose time point; overall possible PID score range at a post-dose time point: -10 to 10, higher positive value=greater improvement. Score range for: SPRID 0-2= -20 to 28; SPRID 0-4= -40 to 56; SPRID 0-6= -60 to 84; SPRID 0-8= -80 to 112. Higher SPRID scores=more improvement in pain.

Time frame:
From 0 to 2, 0 to 4, 0 to 6 and 0 to 8 hours post-dose on Day 1
Reported as:
Least squares mean · units on a scale
Time Weighted Sum of Pain Relief Rating and Pain Intensity Difference Scores From 0 to 2 (SPRID 0-2), 0 to 4 (SPRID 0-4), 0 to 6 (SPRID 0-6) and 0 to 8 Hours Post-dose (SPRID 0-8)
units on a scaleIbuprofen 400 mg + Caffeine 100 mgIbuprofen 400 mgPlacebo
SPRID 0-213.3 ± 0.412.2 ± 0.42.2 ± 0.7
SPRID 0-430.0 ± 0.828.5 ± 0.86.0 ± 1.5
SPRID 0-644.5 ± 1.342.1 ± 1.310.2 ± 2.3
SPRID 0-855.5 ± 1.852.8 ± 1.814.6 ± 3.3
Statistical analysis
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.056 · Ls mean difference: 1.09 · 95% CI -0.03 to 2.20
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 11.13 · 95% CI 9.54 to 12.73
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls mean difference: 10.05 · 95% CI 8.45 to 11.64
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.177 · Ls mean difference: 1.58 · 95% CI -0.72 to 3.87
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls mean difference: 24.04 · 95% CI 20.76 to 27.32
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls mean difference: 22.46 · 95% CI 19.18 to 25.75
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.201 · Ls mean difference: 2.39 · 95% CI -1.28 to 6.06
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls mean difference: 34.30 · 95% CI 29.06 to 39.55
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls mean difference: 31.91 · 95% CI 26.67 to 37.16
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls mean difference: 40.85 · 95% CI 33.49 to 48.20
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls mean difference: 38.17 · 95% CI 30.81 to 45.52
SecondaryTime Weighted Sum of Pain Intensity Difference Scores From 0 to 2 Hours (SPID 0-2), 0 to 4 (SPID 0-4), 0 to 6 (SPID 0-6) and 0 to 8 Hours Post-dose (SPID 0-8)

SPID 0-2, SPID 0-4, SPID 0-6, SPID 0-8: time-weighted sum of PID scores from 0 to 2, 0 to 4, 0 to 6 and 0 to 8 hours post-dose respectively. NPSR scale: at baseline and each post-dose time point participants answered to question "How much pain do you have at this time?" on an 11-point scale: score range from 0 = no pain to 10 = worst possible pain; higher scores = worse pain. PID score: NPSR score at baseline (0 hour) minus NPSR score at each post-dose time point; overall possible PID score range at a post-dose time point: -10 to 10, higher positive value = greater improvement. Overall possible range: SPID 0-2 = -20 to 20; SPID 0-4 = -40 to 40; SPID 0-6 = -60 to 60; SPID 0-8 = -80 to 80. Higher SPID scores = more improvement in pain.

Time frame:
From 0 to 2, 0 to 4, 0 to 6 and 0 to 8 hours post-dose on Day 1
Reported as:
Least squares mean · units on a scale
Time Weighted Sum of Pain Intensity Difference Scores From 0 to 2 Hours (SPID 0-2), 0 to 4 (SPID 0-4), 0 to 6 (SPID 0-6) and 0 to 8 Hours Post-dose (SPID 0-8)
units on a scaleIbuprofen 400 mg + Caffeine 100 mgIbuprofen 400 mgPlacebo
SPID 0-28.7 ± 0.38.0 ± 0.31.2 ± 0.5
SPID 0-419.9 ± 0.618.8 ± 0.63.5 ± 1.0
SPID 0-629.5 ± 0.927.7 ± 0.96.1 ± 1.6
SPID 0-836.6 ± 1.334.6 ± 1.38.8 ± 2.3
Statistical analysis
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.066 · Ls means difference: 0.73 · 95% CI -0.05 to 1.50
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 7.55 · 95% CI 6.44 to 8.66
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 6.82 · 95% CI 5.71 to 7.93
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.165 · Ls means difference: 1.14 · 95% CI -0.47 to 2.74
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 16.35 · 95% CI 14.05 to 18.64
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 15.21 · 95% CI 12.91 to 17.51
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.172 · Ls means difference: 1.78 · 95% CI -0.78 to 4.34
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 23.37 · 95% CI 19.71 to 27.03
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 21.59 · 95% CI 17.93 to 25.25
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.249 · Ls means difference: 2.10 · 95% CI -1.47 to 5.67
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 27.88 · 95% CI 22.78 to 32.99
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 25.79 · 95% CI 20.68 to 30.89
SecondaryTime Weighted Sum of Pain Relief Rating Scores From 0 to 2 (TOTPAR 0-2), 0 to 4 (TOTPAR 0-4), 0 to 6 (TOTPAR 0-6) and 0 to 8 Hours Post-dose (TOTPAR 0-8)

TOTPAR 0-2, TOTPAR 0-4, TOTPAR 0-6, TOTPAR 0-8: time-weighted sum of PRR scores from 0 to 2, 0 to 4, 0 to 6 and 0 to 8 hours post-dose respectively. PRR score: at each post-dose time point participants answered to the question "How much relief do you have from your starting pain?" on a 5-point scale: 0= none, 1= a little, 2= some, 3= a lot, 4= complete; higher scores = more relief from pain. Overall possible range: TOTPAR 0-2 = 0 to 8; TOTPAR 0-4 = 0 to 16; TOTPAR 0-6 = 0 to 24; TOTPAR 0-8 = 0 to 32. Higher TOTPAR scores = more improvement in pain.

Time frame:
From 0 to 2, 0 to 4, 0 to 6 and 0 to 8 hours post-dose on Day 1
Reported as:
Least squares mean · units on a scale
Time Weighted Sum of Pain Relief Rating Scores From 0 to 2 (TOTPAR 0-2), 0 to 4 (TOTPAR 0-4), 0 to 6 (TOTPAR 0-6) and 0 to 8 Hours Post-dose (TOTPAR 0-8)
units on a scaleIbuprofen 400 mg + Caffeine 100 mgIbuprofen 400 mgPlacebo
TOTPAR 0-24.6 ± 0.14.2 ± 0.11.0 ± 0.2
TOTPAR 0-410.2 ± 0.39.7 ± 0.32.5 ± 0.5
TOTPAR 0-615.0 ± 0.414.4 ± 0.44.1 ± 0.7
TOTPAR 0-818.8 ± 0.618.2 ± 0.65.8 ± 1.0
Statistical analysis
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.044 · Ls means difference: 0.36 · 95% CI 0.01 to 0.71
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 3.59 · 95% CI 3.09 to 4.09
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 3.23 · 95% CI 2.73 to 3.73
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.224 · Ls means difference: 0.44 · 95% CI -0.27 to 1.15
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 7.69 · 95% CI 6.68 to 8.71
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 7.25 · 95% CI 6.23 to 8.27
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.293 · Ls means difference: 0.61 · 95% CI -0.53 to 1.75
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 10.93 · 95% CI 9.30 to 12.56
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 10.32 · 95% CI 8.69 to 11.95
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.476 · Ls means difference: 0.58 · 95% CI -1.03 to 2.19
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 12.96 · 95% CI 10.66 to 15.26
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 12.38 · 95% CI 10.08 to 14.68
SecondarySum of Pain Relief Rating and Pain Intensity Difference (PRID) Scores at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, and 8 Hours Post-dose

PRID: sum of PID and PRR at each post-dose time point. PRR score: at each post-dose time point participants answered to a question "How much relief do you have from your starting pain?" on a 5-point scale: 0= none, 1= a little, 2= some, 3= a lot, 4= complete; higher scores = more relief from pain. NPSR scale: at baseline and each post-dose time point participants answered to a question "How much pain do you have at this time?" on an 11-point scale: range from 0= no pain to 10= worst possible pain; higher scores = worse pain. PID score: NPSR score at baseline (0 hour) minus NPSR score at each post-dose time point; overall possible PID score range at a post-dose time point: -10 to 10, higher positive value = greater improvement. At a single post-dose time point overall possible range for PRID score: -10 to 14, higher scores = more improvement in pain.

Time frame:
0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, and 8 hours post-dose on Day 1
Reported as:
Least squares mean · units on a scale
Sum of Pain Relief Rating and Pain Intensity Difference (PRID) Scores at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, and 8 Hours Post-dose
units on a scaleIbuprofen 400 mg + Caffeine 100 mgIbuprofen 400 mgPlacebo
0.25 hour0.8 ± 0.10.8 ± 0.10.7 ± 0.2
0.5 hour3.3 ± 0.23.3 ± 0.21.0 ± 0.4
1 hour7.2 ± 0.26.5 ± 0.21.1 ± 0.4
1.5 hour8.5 ± 0.27.7 ± 0.21.1 ± 0.4
2 hour8.9 ± 0.28.3 ± 0.21.3 ± 0.4
3 hour8.7 ± 0.28.3 ± 0.21.8 ± 0.4
4 hour8.1 ± 0.38.0 ± 0.32.0 ± 0.5
5 hour7.6 ± 0.37.3 ± 0.32.1 ± 0.5
6 hour6.9 ± 0.36.4 ± 0.32.1 ± 0.5
7 hour5.7 ± 0.35.6 ± 0.32.2 ± 0.6
8 hour5.2 ± 0.35.0 ± 0.32.2 ± 0.6
Statistical analysis
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.975 · Ls means difference: 0.01 · 95% CI -0.35 to 0.36
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = 0.654 · Ls means difference: 0.12 · 95% CI -0.40 to 0.63
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = 0.670 · Ls means difference: 0.11 · 95% CI -0.40 to 0.62
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.917 · Ls means difference: -0.04 · 95% CI -0.70 to 0.63
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 2.26 · 95% CI 1.31 to 3.20
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 2.29 · 95% CI 1.35 to 3.24
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.039 · Ls means difference: 0.73 · 95% CI 0.04 to 1.42
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 6.11 · 95% CI 5.12 to 7.10
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 5.38 · 95% CI 4.39 to 6.37
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.015 · Ls means difference: 0.84 · 95% CI 0.16 to 1.52
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 7.36 · 95% CI 6.39 to 8.33
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 6.52 · 95% CI 5.55 to 7.49
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.071 · Ls means difference: 0.62 · 95% CI -0.05 to 1.30
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 7.62 · 95% CI 6.65 to 8.58
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 6.99 · 95% CI 6.03 to 7.96
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.243 · Ls means difference: 0.41 · 95% CI -0.28 to 1.09
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 6.83 · 95% CI 5.85 to 7.80
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 6.42 · 95% CI 5.44 to 7.40
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.823 · Ls means difference: 0.08 · 95% CI -0.65 to 0.82
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 6.08 · 95% CI 5.02 to 7.14
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 6.00 · 95% CI 4.94 to 7.05
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.438 · Ls means difference: 0.31 · 95% CI -0.48 to 1.11
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 5.47 · 95% CI 4.33 to 6.60
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 5.15 · 95% CI 4.01 to 6.29
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.250 · Ls means difference: 0.50 · 95% CI -0.35 to 1.35
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 4.80 · 95% CI 3.58 to 6.02
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 4.30 · 95% CI 3.08 to 5.52
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.818 · Ls means difference: 0.11 · 95% CI -0.80 to 1.01
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 3.53 · 95% CI 2.23 to 4.82
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 3.42 · 95% CI 2.12 to 4.71
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.698 · Ls means difference: 0.18 · 95% CI -0.74 to 1.11
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 3.02 · 95% CI 1.69 to 4.34
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 2.83 · 95% CI 1.51 to 4.16
SecondaryPain Relief Rating Scores at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, and 8 Hours Post-dose

PRR score: at each post-dose time point participants answered to a question "How much relief do you have from your starting pain?" on a 5-point scale: 0= none, 1= a little, 2= some, 3= a lot, 4= complete; higher scores = more relief from pain.

Time frame:
0.25, 0.5, 1, 1.5, 2, 3, 4 5, 6, 7, and 8 hours post-dose on Day 1
Reported as:
Least squares mean · units on a scale
Pain Relief Rating Scores at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, and 8 Hours Post-dose
units on a scaleIbuprofen 400 mg + Caffeine 100 mgIbuprofen 400 mgPlacebo
0.25 hour0.4 ± 0.00.4 ± 0.00.3 ± 0.1
0.5 hour1.3 ± 0.11.2 ± 0.10.5 ± 0.1
1 hour2.5 ± 0.12.3 ± 0.10.5 ± 0.1
1.5 hour2.8 ± 0.12.6 ± 0.10.5 ± 0.1
2 hour3.0 ± 0.12.8 ± 0.10.6 ± 0.1
3 hour2.9 ± 0.12.8 ± 0.10.7 ± 0.1
4 hour2.7 ± 0.12.7 ± 0.10.8 ± 0.1
5 hour2.6 ± 0.12.5 ± 0.10.8 ± 0.2
6 hour2.3 ± 0.12.2 ± 0.10.8 ± 0.2
7 hour2.0 ± 0.12.0 ± 0.10.9 ± 0.2
8 hour1.8 ± 0.11.8 ± 0.10.9 ± 0.2
Statistical analysis
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.575 · Ls means difference: 0.04 · 94% CI -0.09 to 0.16
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = 0.426 · Ls means difference: 0.07 · 95% CI -0.11 to 0.25
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = 0.686 · Ls means difference: 0.04 · 95% CI -0.14 to 0.22
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.543 · Ls means difference: 0.07 · 95% CI -0.15 to 0.29
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 0.81 · 95% CI 0.49 to 1.12
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 0.74 · 95% CI 0.42 to 1.05
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.038 · Ls means difference: 0.24 · 95% CI 0.01 to 0.46
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 2.01 · 95% CI 1.69 to 2.33
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 1.78 · 95% CI 1.46 to 2.09
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.024 · Ls means difference: 0.25 · 95% CI 0.03 to 0.47
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 2.33 · 95% CI 2.02 to 2.64
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 2.08 · 95% CI 1.77 to 2.39
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.103 · Ls means difference: 0.18 · 95% CI -0.04 to 0.40
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 2.40 · 95% CI 2.09 to 2.71
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 2.22 · 95% CI 1.91 to 2.53
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.448 · Ls means difference: 0.08 · 95% CI -0.13 to 0.29
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 2.16 · 95% CI 1.86 to 2.47
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 2.08 · 95% CI 1.78 to 2.38
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.997 · Ls means difference: 0.00 · 95% CI -0.23 to 0.23
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 1.94 · 95% CI 1.61 to 2.28
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 1.94 · 95% CI 1.61 to 2.28
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.656 · Ls means difference: 0.06 · 95% CI -0.19 to 0.31
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 1.73 · 95% CI 1.36 to 2.09
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 1.67 · 95% CI 1.31 to 2.03
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.425 · Ls means difference: 0.11 · 94% CI -0.16 to 0.38
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 1.51 · 95% CI 1.12 to 1.90
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 1.40 · 95% CI 1.01 to 1.79
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.841 · Ls means difference: -0.03 · 95% CI -0.32 to 0.26
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 1.10 · 95% CI 0.69 to 1.52
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 1.13 · 95% CI 0.72 to 1.55
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.980 · Ls means difference: 0.00 · 95% CI -0.30 to 0.30
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 0.93 · 95% CI 0.50 to 1.36
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 0.93 · 95% CI 0.50 to 1.35
SecondaryPain Intensity Difference Scores at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, and 8 Hours Post-dose

NPSR scale: at baseline and each post-dose time point participants answered to a question "How much pain do you have at this time?" on an 11-point scale: range from 0= no pain to 10= worst possible pain; higher scores = worse pain. PID score: NPSR score at baseline (0 hour) minus NPSR score at each post-dose time point; overall possible PID score range at a single post-dose time point: -10 to 10, higher positive value = greater improvement in pain.

Time frame:
0.25, 0.5, 1, 1.5, 2, 3, 4 5, 6, 7, and 8 hours post-dose on Day 1
Reported as:
Least squares mean · units on a scale
Pain Intensity Difference Scores at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, and 8 Hours Post-dose
units on a scaleIbuprofen 400 mg + Caffeine 100 mgIbuprofen 400 mgPlacebo
0.25 hour0.4 ± 0.10.5 ± 0.10.4 ± 0.2
0.5 hour2.0 ± 0.22.1 ± 0.20.6 ± 0.3
1 hour4.7 ± 0.24.2 ± 0.20.6 ± 0.3
1.5 hour5.6 ± 0.25.1 ± 0.20.6 ± 0.3
2 hour5.9 ± 0.25.5 ± 0.20.7 ± 0.3
3 hour5.8 ± 0.25.5 ± 0.21.1 ± 0.3
4 hour5.4 ± 0.25.3 ± 0.21.2 ± 0.3
5 hour5.0 ± 0.24.8 ± 0.21.3 ± 0.3
6 hour4.5 ± 0.24.1 ± 0.21.2 ± 0.4
7 hour3.8 ± 0.23.6 ± 0.21.3 ± 0.4
8 hour3.4 ± 0.23.3 ± 0.21.3 ± 0.4
Statistical analysis
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.808 · Ls means difference: -0.03 · 95% CI -0.27 to 0.21
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = 0.804 · Ls means difference: 0.04 · 95% CI -0.30 to 0.39
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = 0.676 · Ls means difference: 0.07 · 95% CI -0.27 to 0.42
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.654 · Ls means difference: -0.10 · 95% CI -0.55 to 0.35
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 1.45 · 95% CI 0.81 to 2.10
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 1.55 · 95% CI 0.91 to 2.20
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.045 · Ls means difference: 0.49 · 95% CI 0.01 to 0.97
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 4.10 · 95% CI 3.41 to 4.78
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 3.60 · 95% CI 2.92 to 4.29
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.015 · Ls means difference: 0.59 · 95% CI 0.11 to 1.06
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANOVA · p = < 0.001 · Ls means difference: 5.03 · 95% CI 4.35 to 5.71
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 4.44 · 95% CI 3.76 to 5.12
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.066 · Ls means difference: 0.44 · 95% CI -0.03 to 0.91
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 5.22 · 95% CI 4.54 to 5.89
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 4.78 · 95% CI 4.10 to 5.45
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.186 · Ls means difference: 0.32 · 95% CI -0.16 to 0.81
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 4.66 · 95% CI 3.98 to 5.35
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 4.34 · 95% CI 3.65 to 5.03
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.750 · Ls means difference: 0.08 · 95% CI -0.43 to 0.60
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 4.14 · 95% CI 3.40 to 4.87
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 4.05 · 95% CI 3.32 to 4.79
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.361 · Ls means difference: 0.26 · 95% CI -0.30 to 0.81
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 3.74 · 95% CI 2.95 to 4.53
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 3.48 · 95% CI 2.69 to 4.27
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.195 · Ls means difference: 0.39 · 95% CI -0.20 to 0.98
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 3.29 · 95% CI 2.44 to 4.13
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 2.90 · 95% CI 2.06 to 3.74
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.669 · Ls means difference: 0.14 · 95% CI -0.49 to 0.76
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 2.42 · 95% CI 1.53 to 3.31
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 2.29 · 95% CI 1.40 to 3.18
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · ANCOVA · p = 0.581 · Ls means difference: 0.18 · 95% CI -0.46 to 0.82
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 2.09 · 95% CI 1.18 to 3.00
  • Ibuprofen 400 mg vs Placebo · ANCOVA · p = < 0.001 · Ls means difference: 1.91 · 95% CI 1.00 to 2.82
SecondaryTime to Onset of Achieving Meaningful Relief

When the participants were administered study medication at time 0 hours they were given the 2 stopwatches: 1 stopwatch was labelled as "first perceptible relief" and another as "meaningful relief." Participants were instructed to stop the stopwatch labelled as "meaningful relief" at the moment when they first experienced meaningful relief, that is, when the relief from the pain was meaningful to them. The stopwatch remained active for 8 hours (until stopped by the participants, or until rescue medication was administered).

Time frame:
Up to 8 hours post-dose on Day 1
Reported as:
Median · minutes
Time to Onset of Achieving Meaningful Relief
minutesIbuprofen 400 mg + Caffeine 100 mgIbuprofen 400 mgPlacebo
Time to Onset of Achieving Meaningful Relief46.60 (42.82 to 49.15)52.25 (49.15 to 59.18)NA (NA to NA)
Statistical analysis
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · Gehan-Wilcoxon test · p = 0.028P-value was calculated using the Gehan-Wilcoxon test, stratified by gender and baseline categorical pain severity terms.
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · Gehan-Wilcoxon test · p = <0.001P-value was calculated using the Gehan-Wilcoxon test, stratified by gender and baseline categorical pain severity terms.
  • Ibuprofen 400 mg vs Placebo · Gehan-Wilcoxon test · p = <0.001P-value was calculated using the Gehan-Wilcoxon test, stratified by gender and baseline categorical pain severity terms.
SecondaryTime to Onset of First Perceptible Relief

When the participants were administered study medication at time 0 hours they were given the 2 stopwatches: 1 stopwatch was labelled as "first perceptible relief" and another as "meaningful relief." Participants were instructed to stop the stopwatch labelled as "first perceptible relief" at the moment when they first began to feel any pain relieving effect. It was when they first felt a little/noticeable pain relief. It did not mean that they felt completely better (though they might), but when they first felt any difference in pain that they had at present. The stopwatch remained active for 8 hours (until stopped by the participants, or until rescue medication was administered).

Time frame:
Up to 8 hours post-dose on Day 1
Reported as:
Median · minutes
Time to Onset of First Perceptible Relief
minutesIbuprofen 400 mg + Caffeine 100 mgIbuprofen 400 mgPlacebo
Time to Onset of First Perceptible Relief25.80 (21.93 to 29.42)24.52 (22.78 to 26.90)NA (NA to NA)
Statistical analysis
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · Gehan-Wilcoxon test · p = 0.861P-value was calculated using the Gehan-Wilcoxon test, stratified by gender and baseline categorical pain severity terms.
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · Gehan-Wilcoxon test · p = <0.001P-value was calculated using the Gehan-Wilcoxon test, stratified by gender and baseline categorical pain severity terms.
  • Ibuprofen 400 mg vs Placebo · Gehan-Wilcoxon test · p = <0.001P-value was calculated using the Gehan-Wilcoxon test, stratified by gender and baseline categorical pain severity terms.
SecondaryTime to Treatment Failure

Treatment failure was defined as time to first dose of rescue medication or study discontinuation of the participants due to lack of efficacy.

Time frame:
Up to 8 hours post dose on Day 1
Reported as:
Median · minutes
Time to Treatment Failure
minutesIbuprofen 400 mg + Caffeine 100 mgIbuprofen 400 mgPlacebo
Time to Treatment FailureNA (NA to NA)NA (NA to NA)310.00 (132.00 to 480.00)
Statistical analysis
  • Ibuprofen 400 mg + Caffeine 100 mg vs Ibuprofen 400 mg · Gehan-Wilcoxon test · p = 0.838P-value was calculated using the Gehan-Wilcoxon test, stratified by gender and baseline categorical pain severity terms.
  • Ibuprofen 400 mg + Caffeine 100 mg vs Placebo · Gehan-Wilcoxon test · p = <0.001P-value was calculated using the Gehan-Wilcoxon test, stratified by gender and baseline categorical pain severity terms.
  • Ibuprofen 400 mg vs Placebo · Gehan-Wilcoxon test · p = <0.001P-value was calculated using the Gehan-Wilcoxon test, stratified by gender and baseline categorical pain severity terms.
Other pre-specifiedNumber of Participants With Treatment Emergent Adverse Events (AEs) by Severity

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pre-treatment state. AEs are classified according to severity in 3 categories as mild (did not interfere with participant's usual function), moderate (interfered to some extent with participant's usual function) and severe (interfered significantly with participant's usual function).

Time frame:
Screening up to Day 17 after the last dose of study drug (approximately maximum of 48 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity
ParticipantsIbuprofen 400 mg + Caffeine 100 mgIbuprofen 400 mgPlacebo
Mild380
Moderate1278
Severe000
Other pre-specifiedNumber of Participants With Treatment Emergent Treatment Related Adverse Events (AEs)

Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pre-treatment state. Relatedness of an AE to study drug was assessed by investigator.

Time frame:
Screening up to Day 17 after the last dose of study drug (approximately maximum of 48 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Treatment Related Adverse Events (AEs)
ParticipantsIbuprofen 400 mg + Caffeine 100 mgIbuprofen 400 mgPlacebo
Number of Participants With Treatment Emergent Treatment Related Adverse Events (AEs)122
Other pre-specifiedNumber of Participants With Clinically Significant Vital Signs Abnormalities

Vital signs included: heart rate, blood pressure, respiratory rate, and temperature. Normal range for the vital signs were: systolic blood pressure 90 to 140 millimeter of mercury (mmHg), diastolic blood pressure 60 to 90 mmHg, heart rate 50 to 110 beats per minute, respiratory rate 12 to 22 breaths per minute, and oral temperature 97.0 to 99.6 Fahrenheit (F). Value for vital signs outside the normal range was consider as abnormal. Clinical significance of vital signs abnormalities was determined at the investigator's discretion.

Time frame:
Screening up to Day 17 after the last dose of study drug (approximately maximum of 48 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Vital Signs Abnormalities
ParticipantsIbuprofen 400 mg + Caffeine 100 mgIbuprofen 400 mgPlacebo
Number of Participants With Clinically Significant Vital Signs Abnormalities000
Other pre-specifiedNumber of Participants Who Used Concomitant Medications, and Rescue Medications

Rescue medication: participants who did not experience adequate relief after the 1 hour (post study drug dose) evaluation were given tramadol hydrochloride 50 to 100 mg orally or codeine sulfate 15 to 60 mg orally, based on the discretion of the Investigator, as rescue medication. If needed, 2 additional doses of rescue medications based on the discretion of the Investigator at the study center was given. Total maximum dose of tramadol was 300 mg and of codeine sulfate was 180 mg. Concomitant medication: medication received by participant other than study medication and rescue medication.

Time frame:
Day 1
Reported as:
Count of participants · Participants
Number of Participants Who Used Concomitant Medications, and Rescue Medications
ParticipantsIbuprofen 400 mg + Caffeine 100 mgIbuprofen 400 mgPlacebo
Concomitant Medications253911
Rescue Medications292528
Other pre-specifiedNumber of Participants Who Used Medications Prior to This Study

In this outcome measure number of participants who were using any type of medications, prior to start of the study were reported.

Time frame:
At Screening
Reported as:
Count of participants · Participants
Number of Participants Who Used Medications Prior to This Study
ParticipantsIbuprofen 400 mg + Caffeine 100 mgIbuprofen 400 mgPlacebo
Number of Participants Who Used Medications Prior to This Study16116152

Adverse events

Collected over Screening up to Day 17 after the last dose of study drug (approximately maximum 48 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ibuprofen 400 mg + Caffeine 100 mg0/161 (0%)0/161 (0%)15/161 (9.3%)
Ibuprofen 400 mg0/161 (0%)0/161 (0%)15/161 (9.3%)
Placebo0/52 (0%)0/52 (0%)8/52 (15.4%)
Most frequent other events
Showing 10 of 29
Most frequent other events
EventIbuprofen 400 mg + Caffeine 100 mgIbuprofen 400 mgPlacebo
NauseaGastrointestinal disorders4/1614/1617/52
VomitingGastrointestinal disorders3/1612/1616/52
Tooth infectionInfections and infestations0/1611/1611/52
Viral infectionInfections and infestations0/1610/1611/52
Postoperative wound infectionInfections and infestations0/1612/1610/52
Upper respiratory tract infectionInfections and infestations0/1612/1610/52
Alveolar osteitisInfections and infestations2/1610/1610/52
Gilbert's syndromeCongenital, familial and genetic disorders0/1611/1610/52
Vision blurredEye disorders0/1611/1610/52
Aphthous ulcerGastrointestinal disorders0/1611/1610/52

Baseline characteristics

Safety analysis set included all participants who received the study medication.

Age, Continuous
Age, Continuous(years)Ibuprofen 400 mg + Caffeine 100 mgIbuprofen 400 mgPlaceboTotal
Mean19.3 ± 3.0319.1 ± 2.8818.9 ± 2.9319.1 ± 2.95
Sex: Female, Male
Sex: Female, Male(Participants)Ibuprofen 400 mg + Caffeine 100 mgIbuprofen 400 mgPlaceboTotal
Female858427196
Male767725178
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ibuprofen 400 mg + Caffeine 100 mgIbuprofen 400 mgPlaceboTotal
Hispanic or Latino1926853
Not Hispanic or Latino14213544321
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ibuprofen 400 mg + Caffeine 100 mgIbuprofen 400 mgPlaceboTotal
White15314251346
Asian2305
Black or African American2204
American Indian or Alaska Native1102
Native Hawaiian or Other Pacific Islander1708
Other2619
08

Study locations

1 site
  • Jean Brown Research
    Salt Lake City, Utah 84124, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Apr 2018, 5 months.

Results were first posted in Apr 2019, 1 year after primary completion.

Of 105 industry-sponsored phase 3 interventional studies under Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 23. This study's 5 months is below that.

Counting every sponsor, half of 216 studies reached it within 18 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2016
First posted
Aug 11, 2016
StartActual
Oct 24, 2017
Primary completionActual
Apr 6, 2018
CompletionActual
Apr 6, 2018
Results first posted
Apr 8, 2019
Last update
Apr 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02863575
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 11, 2016
Start date
Oct 24, 2017
Primary completion
Apr 6, 2018
Completion
Apr 6, 2018
Results posted
Apr 8, 2019
Last update
Apr 8, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibuprofen · Caffeine

Start the discussion